X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: 1QFY03 net up 36% - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 24, 2002

    Cipla: 1QFY03 net up 36%

    Cipla has reported an encouraging 35% growth in net profits and a corresponding rise in sales for 1QFY03. The growth has been primarily on the back of healthy rise in export sales. Operating margins have registered a 100 basis points rise.

    (Rs m) 1QFY02 1QFY03 Change
    Sales 2,979 4,030 35.3%
    Other Income 61 48 -21.9%
    Expenditure 2,406 3,207 33.3%
    Operating Profit (EBDIT) 573 823 43.6%
    Operating Profit Margin (%) 19.2% 20.4%  
    Interest 3 2 -8.0%
    Depreciation 48 70 47.4%
    Profit before Tax 584 798 36.6%
    Tax 140 192 37.1%
    Profit after Tax/(Loss) 444 606 36.5%
    Net profit margin (%) 14.9% 15.0%  
    No. of Shares (eoy) (m) 60.0 60.0  
    Diluted Earnings per share 29.6 40.4  
    P/E (at current price)   23  

    Turnover was fuelled by a 62% rise in exports from Rs 855 m to 1.39 bn. This rise in mainly on account of bulk exports to USA and Europe. Exports contribution to the total sales was 35% as compared to 29% in the corresponding period last year. Encouragingly, domestic sales grew by 24%, outpacing the domestic industry growth rates. The growth was fuelled by commissioning of the company's Goa unit.

    The timing of launch for CFC-free inhalers to European markets continues to be uncertain. We expect the company to launch the same in Dec' 02. Further, Cipla has tied up with several US generic companies for supply of bulk drugs, which have 'first-to-file status' ('first-to-file status' ensures marketing exclusivity for generic companies). Some of these products are Omeprazole, Flutamide and Olanzipine which are leading molecules in their respective therapeutic segments. Further, the company is exploring options for possible tie-ups for venturing into biotech and genetic engineering with a suitable foreign partner.

    Though the opening up of the African market for anti-AIDS market has provided a big export opportunity for Cipla, the profitability from same is unascertainable at this point of time. Several other companies (including Glaxo, original patent holder) have also offered to supply the drug at concessional rates to African markets. We expect only marginal growth and revenues from this segment.

    One can expect the export momentum of the company to continue and there could be positive surprises on the way. At the current market price of Rs 933, the stock trades at 23x its 1QFY03E earnings.

     

     

    Equitymaster requests your view! Post a comment on "Cipla: 1QFY03 net up 36%". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 23, 2017 (Close)

    TRACK CIPLA

    CIPLA 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE CIPLA WITH

    MARKET STATS